OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull
Cephalalgia · 2025
DOI: 10.1177/03331024251327387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2025. Verfasst von Ho Tin Wong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK. Hauptthemen laut MEDLINE: Migraine Disorders, Botulinum Toxins, Type A, Pregnancy Outcome, Pregnancy Complications. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
OnabotulinumtoxinA is widely used for patients with chronic migraine, but its safety and efficacy in pregnancy remain unclear. In 2020, we published a report of 45 subjects who became pregnant on OnabotulinumtoxinA treatment for chronic migraine. Although numbers were small, the results suggested that OnabotulinumtoxinA treatment was effective in pregnancy without evidence of adverse pregnancy outcome. We now have an additional 81 subjects to add to the database.
Method
This is a tertiary centre (Hull) prospective study between 2010–2024. Subjects who became pregnant during treatment with OnabotulinumtoxinA for chronic migraine were recruited. Subjects were provided informed consent whether to continue treatment with OnabotulinumtoxinA. All subjects were followed up 12-weekly with headache and pregnancy outcomes collected.
Results
Between 2010–2024, 126 subjects became pregnant during OnabotulinumtoxinA treatment for chronic migraine. Of these, 97/126 (77.0%) opted to continue treatment with OnabotulinumtoxinA. All 97/97 (100.0%) subjects who continued OnabotulinumtoxinA treatment remained in migraine remission, compared to only 9/29 (31.0%) who discontinued treatment. 2/97 (2.1%) subjects who continued treatment suffered miscarriages whereas 1/29 (3.4%) subjects who discontinued treatment suffered a miscarriage. No foetal malformations were reported.
Conclusion
In our small descriptive study, subjects who continued OnabotulinumtoxinA in pregnancy continued to have migraine remission with no adverse pregnancy outcomes in our cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK.
- Department of Neurosciences, Hull University Teaching Hospitals, NHS Trust, Hull, UK.
- The Mater Misericordiae University Hospital, The Dublin Neurological Institute, Dublin, Ireland.
- Department of Neurosciences, Spire Hull and East Riding Hospital, Hull, UK.
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
- St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
ORCID-Profile: Ho Tin Wong, Fayyaz Ahmed
Zitieren
APA
Wong, H. T., Khan, R., Buture, A., Khalil, M., & Ahmed, F. (2025). OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull. Cephalalgia. https://doi.org/10.1177/03331024251327387
Vancouver
Wong HT, Khan R, Buture A, Khalil M, Ahmed F. OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull. Cephalalgia. 2025. doi:10.1177/03331024251327387
BibTeX
@article{Wong2025,
author = {Wong, Ho Tin and Khan, Rafiullah and Buture, Alina and Khalil, Modar and Ahmed, Fayyaz},
title = {OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251327387}
}
EUVIMED